AMSTERDAM, Netherlands – An experimental drug from Eli Lilly works best if Alzheimer’s patients are treated as early as possible, ideally before they develop symptoms of the brain-wasting disease, researchers said on Monday, in the latest promising development for treating the most common form of dementia. The drug, donanemab, has been shown to slow progression of memory and thinking problems by…
